Based on original "Signature Base" code by Florian Roth / Neo23x0 @ https://github.com/Neo23x0/signature-base References https://www.bsk-consulting.de/2015/09/06 ...
Abstract: In the ever-evolving cyber era, cyberattack threats are increasingly diverse and elusive. Precise and complete information related to cyber attacks can be utilised to create a reliable ...
Detailed SOL-1 data to be presented at the 49(th) Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), an integrated ...
(RTTNews) - Shares of Ocular Therapeutics, Inc. (OCUL), are up 23% in pre-market trading today, reflecting investor enthusiasm around the company's late-stage pipeline in retinal and glaucoma programs ...
Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...
Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results